Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK2302032A
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GSK2302032A is an investigational antigen-specific cancer immunotherapeutic developed by GSK for use as adjuvant therapy in patients with non-small cell lung cancer (NSCLC). It is designed to stimulate the immune system against tumors expressing the Preferentially Expressed Antigen in Melanoma (PRAME) protein. The drug acts as an immunostimulant and falls under the class of cancer vaccines. Its primary mechanism involves enhancing anti-tumor immune responses by targeting tumor-associated antigens. Clinical development reached phase II trials for NSCLC but has since been discontinued.
- Other names
- PRAME Antigen Specific Cancer Immunotherapeutic - NSCLCPRAME-ASCI-Non-small cell lung cancer
02
Targets
PRAME (Preferentially expressed antigen in melanoma)
Beyond the preview
Go deeper on GSK2302032A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK2302032A.